PPARγ agonists are well-known regulators of glucose and lipid metabolism (15), with established clinical applications in treating metabolic disorders such as type 2 diabetes, dyslipidemia, and non-alcoholic fatty liver disease (44). This evidence concerns the gene PPARG and metabolic disease.